Basic haematological parameters, serum gamma-glutamyl-transferase activity, and erythrocyte folate and serum vitamin B12 levels during carbamazepine and oxcarbazepine therapy

Seizure

Volumn 6, Issue 3, 1997, Pages 207-211

  Isojärvi, Jouko I T ^a   Pakarinen, Arto J ^b   Myllylä, Vilho V ^a  

^a UNIVERSITY OF OULU   (Finland)

^b OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Carbamazepine; Folate; Haematologic parameters; Liver enzyme induction; Oxcarbazepine

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CYANOCOBALAMIN; CYTOCHROME P450; FOLIC ACID; GAMMA GLUTAMYLTRANSFERASE; LIVER ENZYME; OXCARBAZEPINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; EPILEPSY; ERYTHROCYTE; ERYTHROCYTE COUNT; ERYTHROCYTE VOLUME; FEMALE; FOLATE METABOLISM; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; LEUKOCYTE COUNT; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; VITAMIN BLOOD LEVEL;

EID: 0030873031     PISSN: 10591311     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1059-1311(97)80007-6     Document Type: Article

References (26)

1. Killian J.M. Tegretol in trigeminal neuralgia with special reference to hamatopoetic side effects. Headache 1969; 9: 58-63.
2. Livingston S., Pauli L.L. and Berman W. Carbamazepine (Tegretol) in epilepsy: nine year follow-up study with special emphasis on untoward reactions. Diseases of the Nervous System 1974; 35: 103-107.
3. Rodin E.A., Rim C.S. and Rennick P.M. The effects of carbamazepine on patients with psychomotor epilepsy: results of a double-blind study. Epilepsia 1974; 15: 547-561.
4. Hart R.G. and Easton J.D. Carbamazepine and hematological monitoring. Annals of Neurology 1982; 11: 309-312.
5. Joffe R.T., Post R.M., Roy-Byrne P.P. and Uhde T.W. Hematological effects of carbamazepine in patients with affective illness. American Journal of Psychiatry 1985; 142: 1196-1199.
6. Ballenger J.C. The clinical use of carbamazepine in affective disorders. Journal of Clinical Psychiatry 1988; 49(Suppl. 4): 13-21.
7. Evans O.B., Gay H., Swisher A. and Parks B. Hematologic monitoring in children with epilepsy treated with carbamazepine. Journal of Child Neurology 1989; 4: 286-290.
8. Sobotka J.L., Alexander B. and Cook B.L. A review of carbamazepine's haematologic reactions and monitoring recommendations. Drug Intelligence and Clinical Pharmacy 1990; 24: 1214-1219.
9. Dellaportas D.I., Shorvon S.D. Galbraith A.W., Laundy M. and Reynolds E.H. Chronic toxicity in epileptic patients receiving single-drug treatment. British Medical Journal 1982; 285: 409-410.
10. Reynolds E.H. Chronic antiepileptic toxicity: a review. Epilepsia 1975; 16: 319-352.
11. Richens A. and Waters A.H. Acute effects of phenytoin on serum folate concentrations. British Journal of Pharmacology 1971; 41: 414-415.
12. Maxwell J.D., Hunter J., Stewart D.A., Ardeman S. and Williams R. Folate deficiency after anticonvulsant drugs; an effect of hepatic enzyme induction? British Medical Journal 1972; 1: 297-299.
13. Goggin T., Gough H., Bissesar A., Crowley M., Baker M. and Callaghan N. A comparative study of the relative effects of anticonvulsant drugs and dietary folate on the red cell folate status of patients with epilepsy. Quarterly Journal of Medicine 1987; 65: 911-919.
14. al Musaed A.A., Zakrzewska J.M. and Bain B.J. Carbamazepine and folic acid in trigeminal neuralgia patients. Journal of the Royal Society of Medicine 1992; 85: 19-22.
15. Bagy G.C. Jr. Leukopenia. In: Cecil Textbook of Medicine, (Eds J.B. Wyngaarden and L.H. Smith Jr). Philadelphia, W.B. Saunders Company, 1988: Volume 1 pp. 961-977.
16. Beck W.S. Megaloblastic anemias. In: Cecil Textbook of Medicine (Eds j.B. Wyngaarden and L.H. Smith Jr). Philadelphia, W.B. Saunders Company, 1988: Volume 1 pp. 900-961.
17. Houtkooper M.A., Lammertsma A., Meyer J.W.A., et al Oxcarbazepine (GP47 680): a possible alternative to carbamazepine? Epilepsia 1987; 28: 693-698.
18. Dam M., Ekberg R., Loyning Y., Waltimo O. and Jakobsen K. A double-blind study ' comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Research 1989; 3: 70-76.
19. Larkin J.G., McKee P.J.W., Forrest G., et al Lack of enzyme induction with oxcarbazepine (600 mg daily) in healthy subjects. British Journal of Clinical Pharmacology 1991; 31: 65-71.
20. Isojärvi J.I.T., Pakarinen A.J., Rautio A., Pelkonen O. and Myllylä V.V. Liver enzyme induction and serum lipid levels after replacement of carbamazepine with oxcarbazepine. Epilepsia 1994; 35: 1217-1220.
21. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989; 30: 389-399.
22. European Committee for Clinical Laboratory Standards. ECCLS Document NO. 3-4. 1988: 70-85.
23. Park B.K. Assessment of the drug metabolizing capacity of the liver. British Journal of Clinical Pharmacology 1982; 14: 631-651.
24. Mattson R.H., Cramer J.A., Collins J.F., et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized topic-clonic seizures. New England Journal of Medicine 1982; 313: 145-151.
25. Bentsen K.D., Gram L. and Veje A. Serum thyroid hormones and blood folid acid during monotherapy with carbamazepine or valproate. Acta Neurologica Scandinavica 1983; 67: 235-241.
26. Oguni M., Dansky L., Anderman E., Sherwin A. and Anderman F. Improved pregnancy outcome in epileptic women in the last decade: relationship to maternal anticonvulsant therapy. Brain and Development 1992; 14: 371-380.